Home > Insider Trading > Filing (0001578563-17-000002)

Filing Details

Accession Number:: 0001578563-17-000002
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-19 17:53:47
Reporting Period:: 2017-01-17

Filing Date:: 2017-01-19
Accepted Time:: 2017-01-19 17:53:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1208570	Jr B Kenneth Lee	C/O Hatteras Ventures 280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1219890	Alexander Robert Ingram	C/O Hatteras Ventures 280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1291262	Md Douglas Reed	C/O Hatteras Ventures 280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1390733	Hatteras Ventures Partners Iii Lp	280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1390738	Hatteras Venture Affiliates Iii Lp	280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1592380	Clay Thorp	C/O Hatteras Ventures 280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1674107	John Crumpler	C/O Hatteras Ventures 280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes
1674177	Hatteras Venture Advisors Iii, Llc	280 S. Mangum Street, Suite 350 Durham NC 27701	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-01-17	8,366	$8.92	1,774,654	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2017-01-18	10,457	$8.64	1,764,197	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2017-01-19	6,478	$8.22	1,757,719	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
HVP holds 1,611,407 shares and HVA holds 146,312 shares of the Issuer's common stock directly.